

Year(s) Study Active	Name of Study	Sponsor	Principal Investigator	Subject Accrual
COHORT STUDIES				
2008-2010	HIV Elite Controllers Study	Partners AIDS Research Center (Mass. General Hospital)	J. Ravishankar	12
2005-2011	Substance Abuse and HIV: Genetics & Disease Progression	NIMH	H. Crystal	2020
2002-2007	Observational Study of Treated and Untreated Acute and Early HIV-1 Infection	Aaron Diamond AIRDS Research Center	J. DeHovitz	5
2002-2005	HIV Treatment Adherence Demonstration Project	NYS AIDS Institute	T. Wilson	60
1996-1999	Determinants of HIV Testing & Perinatal ZDV Use	Centers for Disease Control and Prevention	H. Minkoff J. DeHovitz	684
1992-2007	Women & Infant Transmission Study (WITS)	NICHD/ NIAID	H. Mendez	300
CLINICAL TRIALS				
2010-2011	A Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults (GS-US-216-0114)	Gilead	J. Ravishankar	0
2007-2008	Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients with Limited to No Treatment Options	Merck	J. Ravishankar	8
2006-2007	A Phase IV, Open-label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on their HAART Regimen.	Bristol Myers Squibb and Gilead Sciences	J. Ravishankar	6
2004-2009	A Phase IV, Multi-center, Cross-sectional Study to Evaluate the I50L Substitution among Subjects Experiencing Virologic Failure on a HAART regimen containing Atazanavir (ATV)	Bristol Myers Squibb	J. Ravishankar	12
2004-2010	A Multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, UK-427,857, in combination with zidovudine/lamivudine versus efavirenz in combination with zidovudine/lamivudine for the treatment of antiretroviral-naïve HIV-1 infected subjects	Pfizer	J. Ravishankar	1
2004-present	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects	Pfizer	J. Ravishankar	3
2004-present	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced, Non CCR5-Tropic HIV-1 Infected Subjects	Pfizer	J. Ravishankar	1
2002	Phase IIIB Atazanavir for HIV Infected Individuals: An Early Access Program	BMS	J. DeHovitz	7
2002-2007	A Large Simple Trial Comparing Two Strategies for Management of Antiretroviral Therapy	NIAID	J. DeHovitz	68
2002	VEST-QD: A Phase IV, Open-label, Randomized, Multi-Center Study Switching HIV-1 Infected Subjects to an Efavirenz Substitution Regimen	BMS	J. DeHovitz	4
1999-2001	Phase IIb study of Indinavir/Ritonavir twice a day plus 3TC/d4T	Merck	J. DeHovitz	4
1999-2001	Phase IV study of gender differences in pharmacokinetics of nelfinavir	Agouron Pharmaceuticals	D. Singh R. Sharma J. Quale	30
1998-2000	Phase IV study of Procrit given weekly	Ortho Biotech	S. Burney J. DeHovitz	14
1998-1999	A Phase IV, Non-Comparative Study to Evaluate FORTOVASE (saquinavir) SGC TID Regimen in Combination with two NRTIs in HIV Infected Women and Men	Roche	J. DeHovitz	2
1998-1999	Phase IV multicenter study of Viracept twice a day	Agouron Pharmaceuticals	J. DeHovitz	10
1999	Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients	Schering Plough	J. DeHovitz	1
1999-2000	A Pilot Multi-Center Open Label Study to Determine the Efficacy and Safety of Serostim in HIV Patients with Unintentional Weight Loss or Body Cell Mass Depletion on Combination Antiretroviral Therapy with or without Protease Inhibitors	Serono Laboratories, Inc.	DeHovitz	1
1992-1997	Adult AIDS Clinical Trials Unit	NIAID	K. Chirgwin	196
1991-2007	Pediatric AIDS Clinical Trials Unit (KCHC)	NICHD/ NIAID	H. Mendez E. Handelsman	50
EARLY ACCESS PROGRAMS				
2002	Phase 2, Double-blind, Randomized, Placebo-Controlled Study of Capravirine in Combination with Viracept	Agouron/ Pfizer	J. DeHovitz	2
2001	Expanded Access Program for Tenofovir DF (Viread)	Gilead Sciences	D. Warren	7
2000-2001	Expanded Access Program for ABT-378r (Kaletra)	Abbott	J. DeHovitz	8
RETROSPECTIVE STUDIES				
1998-2002	HIV Practice Cooperative Phases 1 and 2	Merck & Co.	DeHovitz	160
2000	Nelfinavir Durability	Agouron Pharmaceuticals	Warren	15